


AMENDMENTS TO THE CLAIMS

1-20. (Cancelled).

21. **(Currently Amended)** A compound of the following formula (1):



in which m and n each independently represents 1 or 2,

R¹ represents

hydrogen;

heterocycle which is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and which is unsubstituted, or mono- or polysubstituted by substituents selected from halogen and C₁-C₁₀-alkyl;

-(CH₂)₁₋₃-R⁶, wherein R⁶ is selected from the group consisting of hydrogen, C₁-C₁₀-alkyl, C₁-C₈-alkoxy, heterocycle, hydroxy, C₁-C₈-alkoxycarbonyl, carboxy, amino, C₁-C₁₀-alkylamino, di(C₁-C₁₀-alkyl)amino, and C₁-C₈-alkylcarbonylamino[;], wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C₁-C₁₀-alkyl, C₁-C₈-alkylcarbonyl and C₆-C₁₀-aryloxy;

glycine, alanine, histidine, phenylalanine or proline[;], wherein one or more hydrogen atoms on nitrogen atom are unsubstituted or substituted by a substituent selected from the group consisting of C₁-C₁₀-alkyl, C₁-C₈-alkylcarbonyl, C₁-C₈-alkoxycarbonyl and C₁-C₈-alkylsulfonyl;
 or

-SO₂-C₁-C₃-alkyl,

R² represents

hydrogen;

C₁-C₈-alkyl;

-CO-(CH₂)₁₋₃-hydroxy; or

-CH₂-CO-hydroxy,

R³ represents

C₁-C₈-alkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from C₁-C₈-alkyl and carbamoyl;

-(CH₂)₁₋₃-C₃-C₈-cycloalkyl; or

-(CH₂)₀₋₃-C₆-C₁₀-aryl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, C₁-C₈-alkoxy and C₁-C₈-alkyl,

R⁴ represents

C₁-C₈-alkyl;

-(CH₂)₁₋₃-C₃-C₈-cycloalkyl;

C₃-C₈-cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C₁-C₈-alkyl and C₆-C₁₀-aryl;

spiro[2,5]octan; or

heterocycle which is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring,

R⁵ represents

carbonyl substituted by a substituent selected from the group consisting of C₁-C₈-alkyl, C₁-C₆ alkoxy, C₃-C₇-cycloalkyl, heterocycle and C₆-C₁₀-aryl unsubstituted or substituted by hydroxyl[[;]], wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of amino, C₁-C₈-alkylamino, di(C₁-C₈-alkyl)amino, hydroxy, C₁-C₈-alkoxy, C₆-C₁₀-ar-C₁-C₈-alkyloxy, C₁-C₈-alkyl C₆-C₁₀-aryloxy, C₆-C₁₀-aryloxy, C₆-C₁₀-arylthio, formyl, C₂-C₈-alkanoyloxy, C₃-C₈-cycloalkylcarbonyloxy, C₆-C₁₀-arylcarbonyloxy unsubstituted unsubstituted or substituted by halogen, C₆-C₁₀-ar-C₁-C₈-alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group

consisting of hydroxycarbonyl, C₁-C₈-alkoxycarbonyl, hydroxyl-C₁-C₈-alkyl[[;]], and wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxyC₁-C₈-alkyl, amino and 2-nitrobenzenesulfonyl;

-(CH₂)₁₋₃-C(=O)-C₁-C₆-alkoxy;

carbamoyl which is mono- or polysubstituted by substituents selected from the group consisting of hydrogen, C₁-C₈-alkyl, C₁-C₆-alkoxy, C₃-C₇-cycloalkyl, C₆-C₁₀-aryl and C₁-C₈-alkylcarbonyl substituted by hydroxyl[[;]], wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, amino and C₁-C₈-alkoxy;

-(CH₂)₁₋₃-C(=O)N(C₁-C₈-alkyl)(C₁-C₈-alkyl);

-C(=S)N(H)(C₁-C₈-alkyl) or -C(=S)N(H)(C₁-C₈-alkyl)(C₁-C₈-alkyl); or

-SO₂-NH₂ or -(CH₂)₀₋₃-SO₂-C₁-C₈alkyl,

~~wherein heterocycle includes 1 to 2 heteroatom(s) from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and represents 4 to 8 membered ring which can be fused with benzo or C₃-C₈-cycloalkyl, and which is saturated or has 1 or 2 double bond, or~~

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

22. **(Currently Amended)** The compound according to claim 21, wherein

R¹ represents

hydrogen; or

-(CH₂)₁₋₃-R⁶, wherein R⁶ selected from the group consisting of hydrogen, C₁-C₁₀-alkyl, C₁-C₈-alkoxy, heterocycle, hydroxy, C₁-C₈-alkoxycarbonyl, carboxy, amino, C₁-C₁₀-alkylamino, di(C₁-C₁₀-alkyl)amino, and C₁-C₈-alkylcarbonylamino[[;]], wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C₁-C₁₀-alkyl, C₁-C₈-alkylcarbonyl and C₆-C₁₀-aryloxy; or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

23. (Previously Presented) The compound according to claim 21, wherein R^2 represents hydrogen or C_1 - C_6 -alkyl, or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.
24. (Previously Presented) The compound according to claim 21, wherein R^3 represents $-\text{CH}_2$ -phenyl which is unsubstituted or mono- to tri-substituted by substituents selected from the group consisting of chloro, bromo, hydroxy, methoxy and methyl, or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.
25. (Previously Presented) The compound according to claim 21, wherein R^4 represents C_3 - C_8 -cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C_1 - C_8 -alkyl and C_6 - C_{10} -aryl, or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.
26. **(Currently Amended)** The compound according to claim 21, wherein R^5 represents carbonyl substituted by the substituent selected from the group consisting of C_1 - C_8 -alkyl, C_1 - C_6 -alkoxy, C_3 - C_7 -cycloalkyl, heterocycle and C_6 - C_{10} -aryl unsubstituted or substituted by hydroxyl[;], wherein alkyl is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of amino, C_1 - C_6 -alkylamino, di(C_1 - C_6 -alkyl)amino, hydroxy, C_1 - C_8 -alkoxy, C_6 - C_{10} -ar C_1 - C_8 -alkyloxy, C_1 - C_8 -alkyl C_6 - C_{10} -aryloxy, C_6 - C_{10} -aryloxy, C_6 - C_{10} -arylthio, formyl, C_2 - C_8 -alkanoyloxy, C_3 - C_8 -cycloalkylcarbonyloxy, C_6 - C_{10} -arylcarbonyloxy ~~unsubstituted~~ unsubstituted or substituted by halogen, C_6 - C_{10} -ar- C_1 - C_8 -alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of hydroxycarbonyl, C_1 - C_8 -alkoxycarbonyl, hydroxyl- C_1 - C_8 -alkyl[;], and wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxy C_1 - C_8 -alkyl, amino and 2-nitrobenzenesulfonyl, or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

27. (Previously Presented) An agonistic composition of melanocortin receptor comprising the compound of formula (1), or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof as defined in claim 21 together with a pharmaceutically acceptable carrier.